From the ODAC Poster Hall | Fractional LADD for Non-Surgical Treatment of Superficial Skin Cancer
Surgery is the gold standard for skin cancer treatment, but sometimes surgery isn’t the best option. Perhaps the patient isn’t healthy enough or the patient simply refuses to go under the knife. Topical therapy is an alternative, but patient compliance is a concern. Enter fractional laser-assisted drug delivery (LADD): a non-surgical approach that enhances penetration of topical treatments, le …
Surgery is the gold standard for skin cancer treatment, but sometimes surgery isn’t the best option. Perhaps the patient isn’t healthy enough or the patient simply refuses to go under the knife. Topical therapy is an alternative, but patient compliance is a concern. Enter fractional laser-assisted drug delivery (LADD): a non-surgical approach that enhances penetration of topical treatments, le … 
Following up on insights shared at the ODAC Dermatology Conference, Dr. Neal Bhatia, MD, FAAD, Director of Clinical Dermatology at Therapeutics Clinical Research, offered a comprehensive overview of actinic keratosis (AK) management. Dr. Bhatia emphasized actionable approaches to balancing prescription topicals and procedural techniques in everyday practice.
The incidence for non-melanoma skin … 
Don’t forget about intralesional therapy as a treatment option for cutaneous malignancies, including non-melanoma and melanoma skin cancers, says Dr. Vishal A. Patel, director of cutaneous oncology at the GW Cancer Center. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Patel, who shared in which patients intralesional therapy may be … 
Welcome to the December 2023 issue of the Journal of Drugs in Dermatology (JDD), where cutting-edge research and advancements in the field of dermatology take center stage. This issue brings together a diverse array of original articles, case reports, brief communications, and letters to the editor and delves into the latest developments, therapeutic breakthroughs, and cl … 
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this …